Clinical and genetic risk factors for anthracycline‑induced cardiotoxicity in Chinese early‑stage breast cancer patients: a candidate gene study

Le résumé fourni par la source

PURPOSE: This study aimed to clarify the incidence of anthracycline-induced cardiotoxicity (ACT) and identify its clinical and candidate genetic risk factors in Chinese early-stage breast cancer patients, so as to provide evidence for clinical risk assessment and individualized cardiac protection. METHODS: This study included 119 patients who received anthracycline-based chemotherapy. Cardiac function was assessed via echocardiography at baseline, post-chemotherapy, and at one-year follow-up. Five candidate SNPs (CBR3 rs1056892, GSTP1 rs1695, SLC28A3 rs7853758, ABCB1 rs1045642, ABCC2 rs8187710) were genotyped to analyze their association with ACT. RESULTS: > 0.05). Multivariate logistic regression analysis identified older age, higher cumulative anthracycline dose, and the use of HER2-targeted antibodies (trastuzumab/pertuzumab) as independent clinical risk factors for ACT. CONCLUSION: In Chinese early-stage breast cancer patients, ACT is significantly associated with clinical risk factors rather than the selected candidate genetic polymorphisms. These findings support targeted cardiac monitoring and optimized treatment strategies for high-risk patients to reduce the occurrence of anthracycline-related cardiac injury.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.